Exciting Leadership Change at Zenas BioPharma
Zenas BioPharma, Inc. (NASDAQ: ZBIO), a forward-thinking clinical-stage global biopharmaceutical company dedicated to innovating treatments for autoimmune diseases, has made an impactful leadership change with the appointment of Dr. Haley Laken as its new Chief Scientific Officer (CSO). This strategic move reflects the company's commitment to enhancing its research and development capabilities as it strives to push the boundaries of therapeutic development.
Dr. Laken's Impressive Background
Dr. Laken joins Zenas with a wealth of experience in biopharmaceuticals, specifically in leading research and development initiatives. Her expertise spans translational research and drug development, having successfully guided numerous programs through to regulatory approvals in previous roles at global companies. Her vision aligns perfectly with Zenas’s mission to innovate and lead in the biopharmaceutical industry.
The Vision Ahead
Lisa von Moltke, M.D., the Head of R&D and Chief Medical Officer of Zenas, expressed enthusiasm about Dr. Laken's appointment. She stated, "Haley is an accomplished R&D leader with immense expertise that will be vital as we progress our lead candidate, obexelimab, through Phase 2 and Phase 3 clinical trials. We are also looking forward to expanding our pipeline through strategic business development initiatives under her leadership.” Dr. Laken’s proven track record in transforming drug development processes is expected to drive Zenas toward its ambitious goals.
Commitment to Patient-Centric Treatments
Dr. Laken expressed her eagerness to be part of Zenas during a critical time for the company, stating, "I am excited to collaborate with this accomplished team. Our goal is to advance obexelimab—a therapy targeted at B cells that has the potential to significantly impact patients suffering from IgG4-related diseases, multiple sclerosis, and systemic lupus erythematosus." Her focus on patient outcomes reinforces Zenas’s dedication to creating innovative treatments that make a difference in people’s lives.
Prior Experience and Academic Background
Before her new role at Zenas, Dr. Laken served as Chief Operating Officer at Tabby Therapeutics, where she was instrumental in leading scientific initiatives and company operations. Her career has included critical positions at Jounce Therapeutics, where she was Chief Development Officer, and strategic roles at TESARO, Rhythm Pharmaceuticals, Pfizer, and Wyeth. Dr. Laken holds a Bachelor of Arts in Biology from DePauw University and a Ph.D. in Human Genetics and Molecular Biology from Johns Hopkins University, showcasing her strong academic foundation.
About Zenas BioPharma, Inc.
Zenas is on the forefront of developing and commercializing transformative therapies for patients with autoimmune diseases. The company combines an expert leadership team with a disciplined approach to acquiring and developing product candidates that promise substantial clinical benefits. Their leading candidate, obexelimab, is a novel bifunctional monoclonal antibody designed to effectively address the root causes of many autoimmune disorders without depleting critical B cells. Zenas’s approach aims to provide efficient treatment solutions that can be self-administered through subcutaneous injections, setting a new standard in the industry.
Frequently Asked Questions
Who is the new Chief Scientific Officer at Zenas BioPharma?
Dr. Haley Laken has been appointed as the Chief Scientific Officer, bringing her extensive experience in drug development.
What are the main responsibilities of the new CSO?
Dr. Laken will focus on advancing obexelimab through clinical trials and expanding the company's pipeline.
What is obexelimab?
Obexelimab is Zenas's lead product candidate, a bifunctional monoclonal antibody targeting B cells to treat autoimmune diseases.
What is Zenas BioPharma’s mission?
Zenas aims to lead the development of innovative therapies for autoimmune conditions, improving patient outcomes worldwide.
Where can I find more information about Zenas BioPharma?
For more details, you can visit their official website at www.zenasbio.com and follow them on LinkedIn.
